The TROPION-Breast01 phase III study shows that while the ADC datopotamab deruxtecan (Dato-DXd) improves progression-free survival, it does …
The TROPION-Breast01 phase III study shows that while the ADC datopotamab deruxtecan (Dato-DXd) improves progression-free survival, it does …
A pioneering personalized cancer vaccine, designed using tumor-specific neoantigens, has achieved remission in all nine advanced kidney cancer …
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) modernizes its clinical trial framework with major updates to …
Uvax Bio elevated Chief Business Officer Kevin O’Neill to Interim CEO following the departure of Ji Li, Ph.D., …
Novartis confirmed its acquisition of Anthos Therapeutics for up to $3.1 billion—securing a promising Phase III-stage anticoagulant aimed at …
Atalanta Therapeutics raises $97 million in Series B funding to accelerate RNA interference therapies into Phase 1 trials, …
Allakos faced a major setback as its chronic hives drug AK006 failed to outperform placebo in a key …
Daiichi Sankyo’s antibody–drug conjugate Datopotamab Deruxtecan secures U.S. approval, offering a new treatment for patients with previously treated …
Avance Clinical solidifies its position as the leading early‑phase CRO in Australia—backed by rapid trial starts and generous …
ViGeneron’s VG901 gains momentum with FDA rare pediatric disease status for CNGA1‑linked retinitis pigmentosa, while the EMA urges …
Already a subscriber? Log in